NOPE37: Angiogenic Factors for Managing Term Preeclampsia
ConditionPreeclampsia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorHospital Universitari Vall d'Hebron Research Institute
About this trial
This study tests the hypothesis that, in women with preeclampsia without severe features, delivery management based on sFlt-1/PlGF would reduce the rate of induction of labor without worsening the rate of progression to preeclampsia with severe features and other maternal complications.
Eligibility criteria
Qualifiers
Age ≥18 years
Singleton pregnancy
Preeclampsia without severe features according to the ACOG definition
Antegrade diastolic flow in the umbilical artery Doppler
Disqualifiers
Fetal death
Preeclampsia with severe features according to the ACOG definition, eclampsia, or any condition that requires immediate delivery
Absent or reversed end-diastolic flow in the umbilical artery Doppler
Non-reassuring CTG
Trial design
Treatments tested in this trial
- Intervention arm: expectant management if sFlt-1/PlGF<38
- Standard care: elective delivery at 37 weeks of gestation
Treatment groups
750 Participants
are divided into 2 treatment groupsSponsors and collaborators
Hospital Universitari Vall d'Hebron Research Institute
Lead sponsor
Instituto de Salud Carlos III
Collaborator
Source ClinicalTrials.gov